Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism

• Status: Completed
• Trial end date: 2012-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose is to evaluate the effects of an investigational blood thinner, apixaban, in preventing venous thromboembolic (VTE) recurrence or death in patients who have completed their intended treatment for deep vein thrombosis (DVT) or pulmonary embolism (PE)

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Collaborator: Pfizer
• Treatments: Apixaban

Criteria

Inclusion Criteria:

• Men and women ≥ 18 years of age;

• Clinical diagnosis of Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE);

• Anticoagulant treatment completed

• No recurrence of Venous Thromboembolism (VTE)

Exclusion Criteria:

• Subjects with indications for long-term treatment with a vitamin K antagonist

• Active bleeding or high risk for serious bleeding

• Short life expectancy

• Uncontrolled high blood pressure

• Impaired kidney or liver function